Literature DB >> 29726786

Surface contamination with ten antineoplastic drugs in 83 Canadian centers.

L Chauchat1, C Tanguay1, N J Caron2, S Gagné2, F Labrèche3,4, J F Bussières1,5.   

Abstract

PURPOSE: The aim of this study was to monitor environmental contamination by 10 antineoplastic drugs in Canadian oncology pharmacy and patient care areas. The secondary objective was to explore the impact of factors that may explain contamination.
METHODS: Twelve standardized sites were sampled in each center (six in the pharmacy and six in patient care areas). Each sample was prepared to allow quantification of seven antineoplastic drugs (cyclophosphamide, ifosfamide, methotrexate, cytarabine, gemcitabine, 5-fluorouracil, irinotecan) by UPLC-MS-MS. Docetaxel, paclitaxel and vinorelbine were also detected, but not quantified due to sensibility limitations. The impact of some factors was evaluated compared with a Kolmogorov-Smirnov test for independent samples.
RESULTS: Eighty-three Canadian centers were recruited in 2017. A total of 953 surfaces were sampled, 495 in pharmacy and 458 in patient care areas. Cyclophosphamide was most often found on surfaces (36% of samples positive, 75th percentile 0.0040 ng/cm2). The arm rest (81.7% of samples positive for at least one antineoplastic drug), the front grille inside the hood (78.3%) and the floor in front of the hood (61.4%) were more frequently contaminated. Centers who prepared more antineoplastic drugs per year had higher concentration on different surfaces ( p < 0.0001).
CONCLUSION: Despite growing awareness and implementation of new safe handling guidelines, healthcare centers' surfaces remain contaminated with traces of many antineoplastic drugs. The use of personal protective equipment remains indisputable. Performing an annual monitoring remains a good indicator to monitor trends over time and to compare with similar centers.

Entities:  

Keywords:  Antineoplastic drugs; cyclophosphamide; environmental surveillance; hazardous drugs; occupational exposure

Mesh:

Substances:

Year:  2018        PMID: 29726786     DOI: 10.1177/1078155218773862

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  9 in total

1.  Review of economic data on closed system transfer drug for preparation and administration of hazardous drugs.

Authors:  Annaelle Soubieux; Cynthia Tanguay; Jean Lachaine; Jean-François Bussières
Journal:  Eur J Hosp Pharm       Date:  2019-02-22

2.  Evaluation of Current Hazardous Drug Exposure Control in Community Pharmacy.

Authors:  John Papastergiou; Tom Smiley
Journal:  J Pharm Technol       Date:  2022-02-08

3.  Cross-Sectional Evaluation of Surface Contamination with Antineoplastic Drugs in Canadian Health Care Centres.

Authors:  Delphine Hilliquin; Cynthia Tanguay; Sébastien Gagné; Nicolas J Caron; Jean-François Bussières
Journal:  Can J Hosp Pharm       Date:  2019-10-21

4.  Environmental assessment of cytotoxic drugs in healthcare settings: protocol for a systematic review and meta-analysis.

Authors:  Laila Al Alawi; Elpidoforos S Soteriades; Marilia Silva Paulo; Linda Östlundh; Michal Grivna; Fatima Al Maskari; Rami H Al-Rifai
Journal:  Syst Rev       Date:  2020-10-19

5.  A simple approach to assess the cancer risk of occupational exposure to genotoxic drugs in healthcare settings.

Authors:  Johannes Gerding; Lea Anhäuser; Udo Eickmann; Albert Nienhaus
Journal:  J Occup Med Toxicol       Date:  2022-04-01       Impact factor: 2.646

6.  Occupational Exposure Assessment to Antineoplastic Drugs in Nine Italian Hospital Centers over a 5-Year Survey Program.

Authors:  Cristina Sottani; Elena Grignani; Marco Cornacchia; Sara Negri; Francesco Saverio Robustelli Della Cuna; Danilo Cottica; Dario Bruzzese; Paolo Severi; Daniele Strocchi; Giovanni Verna; Veruscka Leso; Ivo Iavicoli
Journal:  Int J Environ Res Public Health       Date:  2022-07-14       Impact factor: 4.614

7.  Study protocol for the assessment of nurses internal contamination by antineoplastic drugs in hospital centres: a cross-sectional multicentre descriptive study.

Authors:  Antoine Villa; Mathieu Molimard; Emmanuelle Bignon; Béatrice Martinez; Magali Rouyer; Simone Mathoulin-Pelissier; Isabelle Baldi; Catherine Verdun-Esquer; Mireille Canal-Raffin
Journal:  BMJ Open       Date:  2019-11-10       Impact factor: 2.692

8.  Is the blood of a surgeon performing HIPEC contaminated by irinotecan, its major metabolites and platinum compounds?

Authors:  Guillaume Saint-Lorant; Simon Rodier; Jean-Marc Guilloit; Sophie Ndaw; Mathieu Melczer; Stéphanie Lagadu; Agnès Palix; Raphaël Delépée
Journal:  Pleura Peritoneum       Date:  2021-03-03

9.  Evaluation of external contamination on the vial surfaces of some hazardous drugs that commonly used in Chinese hospitals and comparison between environmental contamination generated during robotic compounding by IV: Dispensing robot vs. manual compounding in biological safety cabinet.

Authors:  Hao Ml; Wang T; Zhu Jq; Song Yj; Gong Tj; Zou Lk; Liu J; Yan Jf
Journal:  J Oncol Pharm Pract       Date:  2021-06-24       Impact factor: 1.416

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.